- Home
- MKTW vs ELTX Comparison
MKTW vs ELTX Comparison
Compare MKTW & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | ELTX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 63.3M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MKTW | ELTX |
|---|---|---|
| Price | $18.50 | $2.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $18.00 |
| AVG Volume (30 Days) | 15.9K | ★ 266.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.20% | N/A |
| EPS Growth | ★ 1183.33 | 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $512,403,000.00 | $2,301,000.00 |
| Revenue This Year | $1.52 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.49 | $2.34 |
| 52 Week High | $22.83 | $16.00 |
Technical Indicators
Market Signals| Indicator | MKTW | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 24.01 |
| Support Level | $16.22 | N/A |
| Resistance Level | $21.40 | $3.32 |
| Average True Range (ATR) | 0.56 | 0.13 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 74.16 | 1.09 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.